13148_2020_943_MOESM2_ESM.docx (36.51 kB)
Additional file 2 of BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
journal contribution
posted on 2020-11-11, 04:23 authored by Sylwia Wasiak, Kim E. Dzobo, Brooke D. Rakai, Yannick Kaiser, Miranda Versloot, Mahnoush Bahjat, Stephanie C. Stotz, Li Fu, Michael Sweeney, Jan O. Johansson, Norman C. W. Wong, Erik S. G. Stroes, Jeffrey Kroon, Ewelina KulikowskiAdditional file 4–7. Additional file 4. Apabetalone’s gene targets in IPA® canonical pathways gene sets: Unstimulated control and DM2+CVD monocytes treated with apabetalone ex vivo. Additional file 5. Apabetalone’s gene targets that converge on IPA® upstream regulators: unstimulated monocytes treated with apabetalone ex vivo. Additional file 6. Apabetalone’s gene targets within IPA® canonical pathways: IFNγ stimulated monocytes treated with apabetalone ex vivo. Additional file 7. Apabetalone’s gene targets in IPA® upstream regulators gene sets: IFNγ stimulated control and DM2+CVD patient monocytes treated with apabetalone ex vivo.
